Page 1

Highlights for the quarter Comparative figures for Q1 2019/20 are stated in brackets . Interim report for Q1 2020/21 Ambu delivered organic revenue growth of 39 % in Q1 . The demand for single use endoscopes is positively influenced by COVID - 19 . Commercial launch of aScope TM Duodeno is on track , and clinical trial has commenced . Ambu intends to raise approx . DKK 1.3bn of capital to ensure strategic and operational flexibility . Full - year outlook is maintained . ● " We reached revenue of one billion DKK this quarter for the first time in Ambu's history . This milestone is the result of the dedication and focus of our organization in the midst of the COVID - 19 pandemic . We're leading the creation of the single use endoscopy market to help hospitals take care of patients without risk of cross - contamination . Our modular R & D engine is helping us deliver technologically advanced products with an attractive economic offering across all endoscopy segments , " said CEO Juan Jose Gonzalez . " We have a promising future and are now strengthening our balance sheet to maintain flexibility as we move forward . " ● ● Ambu Ideas that work for life o OK Revenue for Q1 was DKK 1,013m ( DKK 760m ) based on organic growth of 39 % ( 14 % ) . Sales in North America grew organically by 13 % , while we saw organic growth in Europe of 79 % and Rest of World of 9 % . Visualization achieved organic revenue growth of 101 % ( 24 % ) with strong performance across all regions . North America grew organically by 35 % , Europe by 194 % and Rest of World by 35 % . The Visualization growth in Europe benefited from special orders for single - use bronchoscopes to the National Health Service ( NHS ) in England as part of their COVID - 19 strategy to treat patients and build safety stocks . These orders were expected and contributed approx . 40 percentage points of the 101 % organic growth for Visualization in Q1 . Anaesthesia grew 5 % ( 8 % ) , and Patient Monitoring & Diagnostics ( PMD ) declined by -3 % ( 10 % ) . The recovery that we have seen since second half of 2019/20 continued in Q1 , but especially PMD was still negatively impacted by COVID - 19 . Ambu Company announcement no . 7 2020/21 The special orders to the NHS had an impact equal to 16 percentage points to the Q1 organic growth of 39 % . Excluding these orders , organic growth in Q1 would have been 23 % . 27 January 2021 Sales of single - use endoscopes reached 370,000 units for the quarter . Sales volumes were thus up 106 % relative to last year . Page 1